ES2175925T3 - Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. - Google Patents
Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1.Info
- Publication number
- ES2175925T3 ES2175925T3 ES99900012T ES99900012T ES2175925T3 ES 2175925 T3 ES2175925 T3 ES 2175925T3 ES 99900012 T ES99900012 T ES 99900012T ES 99900012 T ES99900012 T ES 99900012T ES 2175925 T3 ES2175925 T3 ES 2175925T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- heterocyclic
- amino
- independently selected
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
5 1. Un compuesto con la siguiente Fórmula: **fórmula** o las sales farmacéuticamente aceptables del mismo, en la que R 1 y R 2 son independientemente alquilo C1-C4; o R 1 y R 2 , junto con el átomo de carbono al que están unidos forman un grupo mono-, bi-, trio espirocíclico que tiene entre 6 y 13 átomos de carbono, en el que el grupo cíclico está opcionalmente sustituido con uno a cinco sustituyentes independientemente seleccionados entre alquilo C1-C4, alquileno C2-C4, alcoxi C1-C4, hidroxi, oxo, =CH2 y =CH-alquilo C1-C4; R 3 es alquilo C1-C7, alquenilo C2-C5, alquinilo C2-C5, fenil-alquilo-C1-C5, fenilo opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre úor, alquilo C1-C3 y alcoxi C1-C3, o un grupo heteroarilo seleccionado entre furilo, tienilo, pirrolilo y piridilo, en el que dicho grupo heteroarilo está opcionalmente sustituido con uno a tres sustituyentes independientemente seleccionados entre halógeno, alquilo C1-C3 y alcoxiC1-C3, con la condición de que cuando ambos R 1 y R 2 son alquilo C1-C4, entonces R 3 es distinto a alquilo C1-C7, alquenilo C2-C5 y alquinilo C2-C5; R 4 se selecciona entre: 1) hidrógeno, 2) alquilo (C1-C8), cicloalquilo (C3-C7), alquenilo (C2-C8), alquinilo (C2-C8), alquilo (C1-C6)-Z-, alquilo (C1-C6)-Z-alquilo (C1-C6), cicloalquilo (C3-C7)-Z-alquilo (C1-C6), alquenilo (C2-C6)-Z-alquilo (C1-C6) o alquinilo (C2-C6)-Z-alquilo (C1-C6), opcionalmente mono o disustituido donde Z se selecciona entre O, S, SO, SO2, CO,CO2, OCO, NR, CONR y NRCO, donde R es hidrógeno o alquilo (C1-C6) y los sustituyentes a unirse al radical alquilo, alquenilo, alquinilo o cicloalquilo se seleccionan independientemente entre halógeno, hidroxi, carboxi, amino, monoo di-(alquil C1-C4)amino, hidrazino, azido, ureido, amidino y guanidino; o 3) arilo, heterocíclico, arilalquilo (C1-C5), heterocíclico alquilo (C1-C5), heterocíclico-heterocíclico alquilo (C1-C5); arilheterocíclico alquilo (C1-C5); heterocíclico-Z-alquilo (C1-C5), aril-Z-alquilo (C1C5), arilalquilo (C1-C5)-Z-alquilo (C1-C5) oheterocíclico alquilo (C1-C5)-Z-alquilo (C1-C5), opcionalmente mono o disustituido, en el que el grupo arilo se selecciona entre fenilo, naftilo, indanilo, (1,2,3,4)-tetrahidronaftilo, indenilo e isoindenilo; el grupo heterocíclico se selecciona entre piperidino, hexametilenimino, morfolino, tiamorfolino, pirrolidino, pirazolino, pirazolidino, pirazorilo, piperazinilo, furilo, tienilo, oxazolilo, tetrazolilo, tiazolilo, imidazolilo, imidazolinilo, pirazolilo, piridilo, pirimidinilo, pirrolilo, pirrolidinilo, quinolilo, tiofenilo, pirazinilo, piridazinilo, aziridinilo y azetidinilo; en el que Z se selecciona entre O, S, SO, SO2, CO,CO2, OCO, NR, CONR y NRCO, en el que R es hidrógeno o alquilo (C1-C6) y los sustituyentes a los que se une el radical arilo o heterocíclico se seleccionan independientemente entre halógeno, hidroxi, carboxi, alquilo (C1-C4), halo alquilo (C1-C4), alcoxi (C1-C4), alquilo (C1-C4)-CO-, alquil (C1-C4) amino-CO-, fenilo, bencilo, amino, monoo di(alquil C1-C4)amino, hidrazino, azido, ureido, amidino y guanidino; R 5 se selecciona independientemente entre halógeno, alquilo C1-C3, alcoxi C1-C3, alquil(C1-C3) sulfonilo, CF3, carboxi, hidroxi, amino, alquilamino, acilamino, arilcarbonilo, alquilcarbonilo e hidroxialquilo y n es 0,1, 2, 3ó 4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB9800069 | 1998-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2175925T3 true ES2175925T3 (es) | 2002-11-16 |
Family
ID=11004651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES99900012T Expired - Lifetime ES2175925T3 (es) | 1998-01-19 | 1999-01-08 | Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6423725B1 (es) |
| EP (1) | EP1049689B1 (es) |
| JP (1) | JP3342478B2 (es) |
| CN (1) | CN1288464A (es) |
| AP (1) | AP9901442A0 (es) |
| AR (1) | AR014421A1 (es) |
| AT (1) | ATE219772T1 (es) |
| AU (1) | AU1679099A (es) |
| BG (1) | BG104670A (es) |
| BR (1) | BR9907104A (es) |
| CA (1) | CA2317462C (es) |
| CO (1) | CO4990962A1 (es) |
| DE (1) | DE69901934T2 (es) |
| DK (1) | DK1049689T3 (es) |
| EA (1) | EA200000683A1 (es) |
| ES (1) | ES2175925T3 (es) |
| GT (1) | GT199900008A (es) |
| IL (1) | IL137149A0 (es) |
| IS (1) | IS5539A (es) |
| MA (1) | MA26598A1 (es) |
| NO (1) | NO20003671L (es) |
| OA (1) | OA11445A (es) |
| PA (1) | PA8467101A1 (es) |
| PE (1) | PE20000166A1 (es) |
| PL (1) | PL342046A1 (es) |
| PT (1) | PT1049689E (es) |
| TN (1) | TNSN99006A1 (es) |
| TR (1) | TR200002090T2 (es) |
| WO (1) | WO1999036421A1 (es) |
| ZA (1) | ZA99314B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262066B1 (en) | 1998-07-27 | 2001-07-17 | Schering Corporation | High affinity ligands for nociceptin receptor ORL-1 |
| DE69923744T2 (de) * | 1998-10-23 | 2006-02-23 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten |
| WO2000031061A1 (en) * | 1998-11-20 | 2000-06-02 | Banyu Pharmaceutical Co., Ltd. | 2-oxoimidazole derivatives |
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| US6686370B2 (en) | 1999-12-06 | 2004-02-03 | Euro-Celtique S.A. | Triazospiro compounds having nociceptin receptor affinity |
| AU1816901A (en) * | 1999-12-06 | 2001-06-12 | Euro-Celtique S.A. | Benzimidazole compounds having nociceptin receptor affinity |
| US6984664B2 (en) | 1999-12-06 | 2006-01-10 | Euro-Celtique, S.A. | Tertiary amino compounds having opioid receptor affinity |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| AU2403802A (en) * | 2000-11-15 | 2002-05-27 | Banyu Pharma Co Ltd | Benzimidazole derivatives |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| KR100628292B1 (ko) | 2001-04-18 | 2006-09-27 | 유로-셀티크 소시에떼 아노뉨 | 스파이로파이라졸 화합물 |
| RU2268883C2 (ru) | 2001-04-18 | 2006-01-27 | Эро-Селтик, С.А. | Аналоги ноницептина и фармацевтическая композиция на их основе |
| EP1385518B1 (en) | 2001-04-18 | 2008-08-06 | Euro-Celtique S.A. | Benzimidazolone compounds |
| IL158484A0 (en) | 2001-04-18 | 2004-05-12 | Euro Celtique Sa | Nociceptin analogs |
| JP4489354B2 (ja) | 2001-04-18 | 2010-06-23 | ユーロ−セルティーク エス．エイ． | スピロインデンおよびスピロインダン化合物類 |
| DE10123163A1 (de) * | 2001-05-09 | 2003-01-16 | Gruenenthal Gmbh | Substituierte Cyclohexan-1,4-diaminderivate |
| JP3896309B2 (ja) | 2001-07-09 | 2007-03-22 | ファイザー株式会社 | プロテインキナーゼｃ阻害物質としてのピラゾロキノリノン誘導体 |
| JP4056977B2 (ja) | 2002-03-29 | 2008-03-05 | 田辺三菱製薬株式会社 | 睡眠障害治療薬 |
| JP2005289816A (ja) * | 2002-05-14 | 2005-10-20 | Banyu Pharmaceut Co Ltd | ベンズイミダゾール誘導体 |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| AU2003296564A1 (en) * | 2002-11-12 | 2004-06-03 | Grunenthal Gmbh | 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives |
| AR045939A1 (es) * | 2003-09-25 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolona y quinazolinona como agonistas de los receptores orl 1 humanos |
| AR045843A1 (es) | 2003-10-03 | 2005-11-16 | Solvay Pharm Bv | Derivados de bencimidazolonas y quinazolinonas sustituidas con hidronopol como agonistas en receptores orl 1 humanos |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US7300947B2 (en) * | 2005-07-13 | 2007-11-27 | Banyu Pharmaceutical Co., Ltd. | N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives |
| AR054816A1 (es) * | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| EP1954137A4 (en) * | 2005-11-18 | 2008-12-17 | Janssen Pharmaceutica Nv | 2-KETO-OXAZOLE AS MODULATORS OF FATTY ACID AMIDHYDROLASE |
| JP2009525269A (ja) | 2006-01-30 | 2009-07-09 | ユーロ−セルティーク エス．エイ． | カルシウムチャネルブロッカーとしての環状尿素化合物 |
| GB0605786D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| GB0605784D0 (en) * | 2006-03-22 | 2006-05-03 | Glaxo Group Ltd | Compounds |
| JP5089687B2 (ja) * | 2006-10-16 | 2012-12-05 | 田辺三菱製薬株式会社 | アルコール依存症または薬物依存症の予防または治療剤 |
| EP2397477B1 (en) * | 2007-01-16 | 2014-03-05 | Purdue Pharma LP | Heterocyclic-substituted piperidine compounds and the uses thereof |
| BRPI0808025A2 (pt) | 2007-03-01 | 2014-06-24 | Mitsubishi Tanabe Pharma Corp | Composto de benzimidazol e uso farmacêutico do mesmo |
| MY150602A (en) | 2007-08-31 | 2014-01-30 | Purdue Pharma Lp | Subtituted-quinoxaline-type piperidine compounds and the uses thereof |
| US8119661B2 (en) | 2007-09-11 | 2012-02-21 | Astrazeneca Ab | Piperidine derivatives and their use as muscarinic receptor modulators |
| TW201016675A (en) | 2008-09-16 | 2010-05-01 | Mitsubishi Tanabe Pharma Corp | Crystalline benzoimidazole compound and salt thereof |
| WO2011157793A1 (en) * | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| WO2014153529A1 (en) | 2013-03-22 | 2014-09-25 | The Scripps Research Institute | Substituted benzimidazoles as nociceptin receptor modulators |
| JPWO2018097291A1 (ja) * | 2016-11-28 | 2019-10-17 | 田辺三菱製薬株式会社 | コカイン依存症の治療または再発予防薬 |
| WO2019141803A1 (en) * | 2018-01-19 | 2019-07-25 | Idorsia Pharmaceuticals Ltd | C5a receptor modulators |
| CN116496270B (zh) * | 2022-01-27 | 2024-09-24 | 四川大学华西医院 | 一类4-氨基哌啶衍生物及其制备方法和用途 |
| CN121843930A (zh) * | 2024-01-05 | 2026-04-10 | 宜昌人福药业有限责任公司 | 一种环己基取代哌啶衍生物、包含其的药物组合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3161645A (en) | 1962-12-18 | 1964-12-15 | Res Lab Dr C Janssen N V | 1-(1-aroylpropyl-4-piperidyl)-2-benzimidazolinones and related compounds |
| US3318900A (en) | 1964-05-06 | 1967-05-09 | Janssen Pharmaceutica Nv | Derivatives of benzimidazolinyl piperidine |
| JPS58180481A (ja) * | 1982-04-15 | 1983-10-21 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
| AT388731B (de) * | 1987-12-15 | 1989-08-25 | Gerot Pharmazeutika | Neue derivate von benzimidazol, ihre herstellung und verwendung |
| AU7478396A (en) | 1995-10-31 | 1997-05-22 | Merck & Co., Inc. | Muscarine agonists |
| ZA9610745B (en) * | 1995-12-22 | 1997-06-24 | Warner Lambert Co | 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists |
| US6180649B1 (en) * | 1996-04-19 | 2001-01-30 | Nerosearch A/S | 1-(4-piperidyl)-benzimidazoles having neurotrophic activity |
| ES2226129T3 (es) | 1997-05-30 | 2005-03-16 | Banyu Pharmaceutical Co., Ltd. | Derivados de 2-0x0imidazol. |
-
1999
- 1999-01-08 AU AU16790/99A patent/AU1679099A/en not_active Abandoned
- 1999-01-08 US US09/403,408 patent/US6423725B1/en not_active Expired - Fee Related
- 1999-01-08 AT AT99900012T patent/ATE219772T1/de not_active IP Right Cessation
- 1999-01-08 EP EP99900012A patent/EP1049689B1/en not_active Expired - Lifetime
- 1999-01-08 CN CN99802227A patent/CN1288464A/zh active Pending
- 1999-01-08 WO PCT/IB1999/000012 patent/WO1999036421A1/en not_active Ceased
- 1999-01-08 DK DK99900012T patent/DK1049689T3/da active
- 1999-01-08 JP JP2000540137A patent/JP3342478B2/ja not_active Expired - Fee Related
- 1999-01-08 ES ES99900012T patent/ES2175925T3/es not_active Expired - Lifetime
- 1999-01-08 DE DE69901934T patent/DE69901934T2/de not_active Expired - Fee Related
- 1999-01-08 CA CA002317462A patent/CA2317462C/en not_active Expired - Fee Related
- 1999-01-08 PT PT99900012T patent/PT1049689E/pt unknown
- 1999-01-08 BR BR9907104-5A patent/BR9907104A/pt not_active Application Discontinuation
- 1999-01-08 IL IL13714999A patent/IL137149A0/xx unknown
- 1999-01-08 PL PL99342046A patent/PL342046A1/xx not_active Application Discontinuation
- 1999-01-08 EA EA200000683A patent/EA200000683A1/ru unknown
- 1999-01-08 TR TR2000/02090T patent/TR200002090T2/xx unknown
- 1999-01-14 AP APAP/P/1999/001442A patent/AP9901442A0/en unknown
- 1999-01-15 PA PA19998467101A patent/PA8467101A1/es unknown
- 1999-01-15 MA MA25432A patent/MA26598A1/fr unknown
- 1999-01-15 TN TNTNSN99006A patent/TNSN99006A1/fr unknown
- 1999-01-18 ZA ZA9900314A patent/ZA99314B/xx unknown
- 1999-01-18 AR ARP990100184A patent/AR014421A1/es unknown
- 1999-01-18 PE PE1999000041A patent/PE20000166A1/es not_active Application Discontinuation
- 1999-01-19 GT GT199900008A patent/GT199900008A/es unknown
- 1999-01-19 CO CO99002592A patent/CO4990962A1/es unknown
-
2000
- 2000-06-16 IS IS5539A patent/IS5539A/is unknown
- 2000-07-07 OA OA1200000203A patent/OA11445A/en unknown
- 2000-07-18 NO NO20003671A patent/NO20003671L/no not_active Application Discontinuation
- 2000-08-07 BG BG104670A patent/BG104670A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2317462A1 (en) | 1999-07-22 |
| US6423725B1 (en) | 2002-07-23 |
| NO20003671L (no) | 2000-09-18 |
| AU1679099A (en) | 1999-08-02 |
| CO4990962A1 (es) | 2000-12-26 |
| ZA99314B (en) | 2000-07-18 |
| PL342046A1 (en) | 2001-05-21 |
| OA11445A (en) | 2004-04-30 |
| EP1049689A1 (en) | 2000-11-08 |
| PA8467101A1 (es) | 2000-09-29 |
| WO1999036421A1 (en) | 1999-07-22 |
| AP9901442A0 (en) | 1999-03-31 |
| PT1049689E (pt) | 2002-09-30 |
| DE69901934T2 (de) | 2002-11-07 |
| DK1049689T3 (da) | 2002-07-22 |
| TR200002090T2 (tr) | 2000-11-21 |
| PE20000166A1 (es) | 2000-03-07 |
| ATE219772T1 (de) | 2002-07-15 |
| BG104670A (en) | 2001-05-31 |
| JP2002509148A (ja) | 2002-03-26 |
| GT199900008A (es) | 2000-07-12 |
| MA26598A1 (fr) | 2004-12-20 |
| EP1049689B1 (en) | 2002-06-26 |
| CA2317462C (en) | 2005-09-13 |
| TNSN99006A1 (fr) | 2005-11-10 |
| CN1288464A (zh) | 2001-03-21 |
| IS5539A (is) | 2000-06-16 |
| EA200000683A1 (ru) | 2000-12-25 |
| NO20003671D0 (no) | 2000-07-18 |
| IL137149A0 (en) | 2001-07-24 |
| DE69901934D1 (de) | 2002-08-01 |
| JP3342478B2 (ja) | 2002-11-11 |
| AR014421A1 (es) | 2001-02-28 |
| BR9907104A (pt) | 2000-10-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2175925T3 (es) | Compuestos 4-(2-ceto-1-benzilimidazolinil)piperidina como agonistas del receptor orl1. | |
| AR066669A1 (es) | Derivados de imidazolona como inhibidores de bencimidazolona quimasa. composiciones farmaceuticas. | |
| CO5631432A2 (es) | Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| NO20044866L (no) | Pyrazolo-pyrimidin-anilin-forbindelser anvendelige som kinase-inhibitorer | |
| CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
| PE20020585A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
| AR118724A1 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| AR045587A1 (es) | Derivados de acil piperazinas sustituidas, proceso de obtencion, uso y composiciones farmaceuticas que las contienen | |
| CO5540299A2 (es) | Derivados de tiazol u oxazol que son utiles en el tratamiento de enfermedades cardiovasculares y relacionadas | |
| CO6170361A2 (es) | Composiciones y metodos para modular receptores de c-kit y pdgfr | |
| MX2007003433A (es) | Sintesis de n-fluorobencil) -n- (1-metilpiperidin-4-il) -n'- (4- (2-metilpropiloxi) fenilmetil) carbamida y su sal de tartrato y formas cristalinas. | |
| AR015770A1 (es) | DERIVADOS DE ÁCIDO PIRIDIN-3-CARBOXíLICO uTILES COMO INTERMEDIARIOS EN LA PREPARACIoN DE PIRAZOLO PIRIMIDINONAS. | |
| CO5670367A2 (es) | Derivados de acido fenoxiacetico | |
| ECSP088479A (es) | Derivados de oxadiazol | |
| CR8468A (es) | Derivado de n-(1,5-difenil-1h-pirazol-3-il)metil)sulfonamida con afinidad por los receptores cb1 | |
| HN2005000030A (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
| CO5611152A2 (es) | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen | |
| RU2012143212A (ru) | Способ лечения артрита | |
| NI200800247A (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen. | |
| CO5601039A2 (es) | Oxazolidinonas de indolona y derivados de las mismas | |
| CO4920224A1 (es) | Compuestos de pirrolidinil y pirrolinil etilamina como agonistas kappa | |
| NO20074346L (no) | Nye heterocykliske oksimforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem | |
| CO5590858A2 (es) | Composicion fungicida basada en un derivado de piridilmetilbenzamida e iprovalicarb | |
| ES2249636T3 (es) | Triazoles como antagonistas de la oxitocina. | |
| CY1110623T1 (el) | Νεα παραγωγα ινζολιζινης, η διαδικασια παραγωγης και οι θεραπευτικες ενωσεις που τα περιεχουν |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 1049689 Country of ref document: ES |